Bookmark
Forward
Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.
Kebede H Begna, Naseema Gangat, Aref Al-Kali, Mark R Litzow, William J Hogan, Mrinal M Patnaik, Animesh Pardanani, C Christopher Hook, Alexandra P Wolanskyj, Michelle A Elliott, Curtis A Hanson, Rhett P Ketterling, Ayalew Tefferi
American journal of hematology 2021 Apr 01
Sizes of these terms reflect their relevance to your search.
No abstract available.
Citation
Kebede H Begna, Naseema Gangat, Aref Al-Kali, Mark R Litzow, William J Hogan, Mrinal M Patnaik, Animesh Pardanani, C Christopher Hook, Alexandra P Wolanskyj, Michelle A Elliott, Curtis A Hanson, Rhett P Ketterling, Ayalew Tefferi.
Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.
American journal of hematology.
2021 Apr 01;96(4):E108-E111
Mesh Tags
Abnormal Karyotype
Age of Onset
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic
Antineoplastic Combined Chemotherapy Protocols
Bridged Bicyclo Compounds, Heterocyclic
CCAAT-Enhancer-Binding Proteins
DNA Methylation
Female
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute
Male
Middle Aged
Myelodysplastic Syndromes
Myeloproliferative Disorders
Neoplasm Proteins
Prognosis
Proportional Hazards Models
Remission Induction
Sulfonamides
Substances
Antimetabolites, Antineoplastic
Bridged Bicyclo Compounds, Heterocyclic
CCAAT-Enhancer-Binding Proteins
CEBPA protein, human
Neoplasm Proteins
Sulfonamides
venetoclax
PMID: 33527451
View Full Text